Pharming Group announces that the Notice to Convene for its Annual General Meeting of Shareholders has been uploaded on its website. Pharming’s upcoming Annual General Meeting will be held at the Holiday Inn (Haagse Schouwweg 10, 2332 KG Leiden, The Netherlands) on 22 May 2019 at 14:00 CEST.
Pharming announces that it has completed its investment of €1.6 million in cash and conversion of €2.5 million of prepayments into new equity in its Fill & Finish partner BioConnection BV.
Pharming Group announces the publication of its Annual Report for the financial year ended 31 December 2018, and a provisional commitment to invest in supplier BioConnection BV.
Pharming Group N.V. presents its preliminary (unaudited) financial report for the full year ended 31 December 2018.
Pharming Webinar: Jaarcijfers 2018 donderdag 7 maart 2019 tussen 19.00 en 20.00 uur. Nu aanmelden!
Pharming Group N.V. announced today that an abstract was presented this week at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Francisco, CA. Additionally, Pharming is pleased to announce sponsorship of the AAAAI Foundation Michael M. Frank, MD, FAAAAI Lectureship.
Today Pharming announces that two abstracts were presented at The Western Society of Allergy, Asthma and Immunology (WSAAI) in Maui, Hawaii, USA on January 22-24, 2019.
Today Pharming acknowledged presentation of the results from an investigator-initiated comparative study of therapies in acute attacks of hereditary angioedema (“HAE”).
Pharming presents its (unaudited) interim financial report for the first nine months and the third quarter ended 30 September 2018.
Today Pharming announced positive results from a Phase II investigator-initiated study of RUCONEST® (recombinant human C1 esterase inhibitor, or “rhC1INH”) in a double-blind, placebo-controlled clinical trial in patients at risk of nephropathy resulting from contrast-enhanced examinations.
